FOE OR FRIEND? SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS AND COVID-19 VACCINATION: A SYSTEMATIC REVIEW
- Author:
Maureen Miracle Stella
1
;
Maureen Miracle Tanadi
1
;
Kevin Tandarto
2
;
Kenny Wijaya Sutanto
1
;
Cindy Oey
3
Author Information
- Publication Type:Review
- Keywords: SLE; COVID-19 vaccination; Antibody response; Disease status
- From: Journal of University of Malaya Medical Centre 2024;27(2):57-68
- CountryMalaysia
- Language:English
- Abstract: FOE OR FRIEND? SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS AND COVID-19 VACCINATION: A SYSTEMATIC REVIEW:Background: In the early year of 2020, SARS-CoV-2 was first diagnosed in Indonesia after an outbreak in Wuhan, China. Later, this disease became a worldwide pandemic. Systemic lupus erythematosus (SLE) patients are more vulnerable to COVID-19. They are also prone to relapse and have lower efficacy for COVID-19 immunization. Objective: This study aimed to evaluate the antibody seroconversion and disease status after COVID-19 vaccination in SLE patients. Method: We followed the PRISMA guidelines to systematically search and collect literature in the following databases: ProQuest, PubMed, EBSCOhost, SAGE, JSTOR, and ScienceDirect from 1st January 2019 to 24th April 2023. Titles and abstracts were reviewed for relevance. The inclusion criteria are original articles, written in English, investigated the effects of COVID-19 vaccination in SLE patients. The quality of evidence was evaluated using the Newcastle-Ottawa Scale. Results and Discussion: From 1,088 studies, we retrieved nine studies for this review. There were cohort studies (n = 5), case-control studies (n = 2), and observational studies (n = 2) published between 2021 and 2022. Vaccines against SARS-CoV-2 are currently widely available and SLE patients should receive vaccination. In a large study involving healthy individuals and healthcare professionals, nearly all of the individuals who received two doses of BNT162b2 developed antibodies to the vaccine. Seroconversion after a first COVID-19 vaccination is delayed in older patients on specific immunosuppressive drugs. Conclusion: This systematic review found that the overall immunogenicity and safety of COVID-19 vaccines were satisfactory in patients with SLE.
- Full text:2026073010100626616FOE OR FRIEND.pdf
